Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.06), Bloomberg Earnings reports. During the same period last year, the business posted ($0.62) EPS.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/02/sunesis-pharmaceuticals-inc-snss-issues-earnings-results-misses-estimates-by-0-06-eps.html.

A number of equities analysts recently issued reports on SNSS shares. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Thursday, July 27th. Finally, ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

In related news, Director Dayton Misfeldt bought 400,000 shares of the company’s stock in a transaction on Friday, October 27th. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $800,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.21% of the company’s stock.

A hedge fund recently raised its stake in Sunesis Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 4.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 605,759 shares of the biopharmaceutical company’s stock after purchasing an additional 23,819 shares during the quarter. Vanguard Group Inc. owned 2.58% of Sunesis Pharmaceuticals worth $1,635,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 57.56% of the stock is currently owned by institutional investors.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.